Lori Muffly, MD

Articles

CAR T-cell Therapy: Mechanisms of Actions of Brexucabtagene Autoleucel and Obecabtagene Autoleucel

Elias Jabbour, MD;Evandro D. Bezerra, MD;Lori Muffly, MD;Jae H. Park, MD;Gregory W. Roloff, MD

June 27th 2024

Dr. Lori Muffly explains the general mechanism of action in CAR T-cell therapy and compares the distinct features of Brexucabtagene autoleucel (Brexu-cel), Tisagenlecleucel (Tisa-cel), and Obecabtagene autoleucel (Obe-cel).

Overview of CAR T-cell Therapies in R/R B-cell ALL

Elias Jabbour, MD;Evandro D. Bezerra, MD;Lori Muffly, MD;Jae H. Park, MD;Gregory W. Roloff, MD

June 27th 2024

Evandro D. Bezerra, MD, provides an overview of current CAR T-cell therapies for relapsed/refractory B-cell acute lymphoblastic leukemia and explores emerging CAR T products under investigation.

Dr. Muffly on the Evaluation of Briquilimab Conditioning Prior to HSCT in AML

Lori Muffly, MD

February 28th 2023

Lori Muffly, MD, discusses the clinical outcomes with the use of a novel conditioning regimen featuring the anti-CD117 monoclonal antibody briquilimab plus low-dose irradiation and fludarabine prior to allogeneic hemopoietic stem cell transplant in older patients with acute myeloid leukemia.